Ceftizoxime
Ceftizoxime is a third-generation cephalosporin available for parenteral administration. Unlike other third-generation cephalosporins, the whole C-3 side chain in ceftizoxime has been removed to prevent deactivation by hydrolytic enzymes. It rather resembles cefotaxime in its properties, but is not subject to metabolism. It was removed from the US Market in 2007.
 | |
| Clinical data | |
|---|---|
| Trade names | Cefizox |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a684043 |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.210.846  |
| Chemical and physical data | |
| Formula | C13H13N5O5S2 |
| Molar mass | 383.40 g·mol−1 |
Synthesis
Injectable third generation cephalosporin antibiotic related to cefotaxime, q.v. Exhibits broad spectrum activity and resistance to β-lactamase hydrolysis.
Ceftizoxime synthesis:[1]
gollark: I think I got a CB copper for one.
gollark: You actually count them accurately enough to get percentages?
gollark: From what? Prizekins or prizes?
gollark: I generally need bolts anyway, sooo...
gollark: I'm sure *someone* wants prizekins.
References
- T. Takaya et al., DE 2810922; eidem, U.S. Patent 4,427,674 (1978, 1984 both to Fujisawa).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.